Author/Authors :
Akbari, Mojtaba Department of Epidemiology - School of Health - Shiraz University of Medical Sciences , Fararouei, Mohammad Department of Epidemiology - School of Health - Shiraz University of Medical Sciences , Haghdoost, Ali Akbar Department of Epidemiology and Biostatistics - Public Health School - Kerman University of Medical Sciences, Kerman , Gouya, Mohammad Mahdi , Afsar Kazerooni, Parvin Shiraz University of Medical Sciences, Shiraz
Abstract :
Background: The survival in Iranian HIV/AIDS patients based on data from Iran National HIV/AIDS Case Registry System has
not been evaluated. This study assessed the survival rates and associated factors among people living with HIV/AIDS in Iran.
Materials and Methods: The population in this observational study included 32168 patients diagnosed with HIV/AIDS registered in
Iran disease registry system between 1986 and 31 December 2015. Data until June 2016 (the cutoff date of our last data linkage) were
investigated to estimate survival and related factors following HIV diagnosis. Results: Of registered patients, 17.7% were diagnosed
at AIDS stage. By June 2016, 27.2% of study population progressed to AIDS, and 8081 (25.1%) of patients died. The survival rate was
88%, 85%, 77%, and 67% for 1, 2, 5, and 10 years, respectively. Cumulative proportion surviving was significantly lower in males than
in females (P = 0.0001). A higher rate of survival was seen in female patients, who diagnosed after 2010, infected in sexual route, and
had CD4 cell count more than 500, nonconfected patients with tuberculosis (TB), and those who received antiretroviral therapy (ART).
Based on multivariate model, the mortality risk in female patients, those with CD4 cell count more than 500, patients who received
ART, and those with TB and injection drug uses (IDUs) was higher. Conclusion: The survival in studied patients increased in recent
time periods, and ART reduced AIDS‑related mortality in these patients. The survival can be increased by focus on improvements
in patient care among male patients, IDUs, and patients with TB coinfection.
Keywords :
Antiretroviral therapy , HIV/AIDS , Iran , survival